Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

LAMA3 Gene Sequencing for Generalized Atrophic Benign Epidermolysis Bullosa (Junctional EB) in UAE | 2800 AED | Certified DHA Facility

Executive Summary & Core Metrics

Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).

Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM) across Dubai, Abu Dhabi, and Sharjah.

Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with Consultant Medical Genetics Lina Osama Zaki Quteineh (DHA ID: 9294403).

Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced molecular test utilises Next Generation Sequencing (NGS) on the Illumina® platform to interrogate the entire coding region of the LAMA3 gene. It identifies single nucleotide variants, small insertions, and deletions linked to generalized atrophic benign epidermolysis bullosa, a mild junctional EB subtype. Accurate molecular confirmation enables early clinical management, carrier testing, and recurrence risk assessment.

Feature Our LAMA3 NGS Test Closest Alternative (Targeted Sanger Sequencing / Clinical Diagnosis)
Precision 99.9% sensitivity for single nucleotide variants, small indels across entire coding region ~95% sensitivity, only targeted known mutation hotspots
Method Next Generation Sequencing (Illumina® platform) with bioinformatic confirmation Sanger sequencing of limited exons or clinical observation alone
Turnaround Time 3–4 Weeks 4–6 Weeks (Sanger) / Immediate clinical suspicion only

Physician Insight & Safety Protocols

“While this NGS assay provides definitive molecular confirmation of LAMA3-related junctional EB, clinical correlation by a dermatologist and geneticist remains paramount. I advise all patients to combine genetic results with a thorough skin fragility assessment. Genetic counselling is mandatory to interpret inheritance patterns and reproductive options.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Safety Exclusion Criteria & ER Red Flags

  • Do not undergo testing if you have a severe active skin infection or sepsis requiring urgent care.
  • Minors must have a court-appointed guardian’s consent as per Federal Decree-Law No. 41 of 2021 on personal data; genetic counselling is mandatory prior to testing for all minors.
  • This test is not a substitute for emergency wound management; if you experience sudden worsening blisters with fever, shortness of breath, or swallowing difficulty, seek immediate emergency care.
  • Recent blood transfusion (< 2 weeks) may interfere with DNA integrity when using whole blood; discuss with our genetic counsellor for alternative sample collection (bucal swab or FTA card).

Exclusion Criteria & Medication Advisory

Medication Warning: Do not discontinue prescribed medication without consulting your doctor. This genetic test does not replace ongoing dermatological care.

Patient FAQ & Clinical Guidance

1. What does the LAMA3 gene test detect and why is NGS better?

The LAMA3 NGS test detects inherited changes in the entire LAMA3 gene causing generalized atrophic benign epidermolysis bullosa, offering a definitive molecular diagnosis in 3–4 weeks. NGS provides comprehensive coverage, identifying variants that Sanger sequencing might miss.

2. Is a blood sample always required, or can I use a buccal swab?

We accept whole blood, extracted DNA, or one drop of blood on an FTA card; a simple, virtually painless collection is performed by our home phlebotomy team within 60 minutes in Dubai, Abu Dhabi, and Sharjah.

3. Will my insurance cover this genetic test and how do I verify?

Many UAE insurance plans reimburse diagnostic genetic testing for hereditary skin disorders; send a photo of your insurance card via WhatsApp to +971 54 548 8731 for instant pre-approval verification.

4. What is the sample type required for this test?

The preferred sample type is peripheral whole blood (3-5 mL in EDTA tube). Buccal swab or FTA card are acceptable alternatives. All samples are processed via temperature-controlled cold-chain courier.

UAE Regulatory & Data Privacy Adherence

  • Data Privacy: All patient data is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
  • Health Data Protection: Compliant with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
  • Patient Consent & Safety: Clinical testing safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
  • DHA License: Operated under DHA Facility License No. 1143.
  • Quality Certification: ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name LAMA3 Gene Sequencing for Generalized Atrophic Benign Epidermolysis Bullosa
Price (AED) 2,800 AED
Turnaround Time 3–4 Weeks
Sample Type / Matrix Peripheral Whole Blood (EDTA), Buccal Swab, or FTA Card
Methodology Used Next Generation Sequencing (Illumina® platform) with bioinformatic confirmation
ICD-10-CM Code Q81.9
LOINC Code 9489-2
DHA Facility License & Address DHA Facility License No: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
WhatsApp Enquiry & Book Home Collection

DHA Licensed Facility | ISO 9001:2015 Certified | Results in 3–4 Weeks

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians